25 XP   0   0   10

Cyclacel Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse Cyclacel together

PenkeI guess you are interested in Cyclacel Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Cyclacel Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Cyclacel Pharmaceuticals Inc

I send you an email if I find something interesting about Cyclacel Pharmaceuticals Inc.

Quick analysis of Cyclacel (30 sec.)










What can you expect buying and holding a share of Cyclacel? (30 sec.)

How much money do you get?

How much money do you get?
€0.13
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
€4.71
Expected worth in 1 year
€7.47
How sure are you?
23.5%

+ What do you gain per year?

Total Gains per Share
€2.87
Return On Investment
88.2%

For what price can you sell your share?

Current Price per Share
€3.26
Expected price per share
€3.257 - €3.257
How sure are you?
50%

1. Valuation of Cyclacel (5 min.)




Live pricePrice per Share (EOD)

€3.26

Intrinsic Value Per Share

€-226.40 - €-270.48

Total Value Per Share

€-221.68 - €-265.77

2. Growth of Cyclacel (5 min.)




Is Cyclacel growing?

Current yearPrevious yearGrowGrow %
How rich?$4.2m$31.8m-$20.8m-189.1%

How much money is Cyclacel making?

Current yearPrevious yearGrowGrow %
Making money-$6.1m-$4.7m-$1.4m-22.8%
Net Profit Margin-9,790.1%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Cyclacel (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#773 / 1031

Most Revenue
#627 / 1031

Most Profit
#501 / 1031

Most Efficient
#957 / 1031

What can you expect buying and holding a share of Cyclacel? (5 min.)

Welcome investor! Cyclacel's management wants to use your money to grow the business. In return you get a share of Cyclacel.

What can you expect buying and holding a share of Cyclacel?

First you should know what it really means to hold a share of Cyclacel. And how you can make/lose money.

Speculation

The Price per Share of Cyclacel is €3.257. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Cyclacel.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Cyclacel, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €4.71. Based on the TTM, the Book Value Change Per Share is €0.69 per quarter. Based on the YOY, the Book Value Change Per Share is €-0.55 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.03 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Cyclacel.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps-7.16-219.7%-3.68-112.9%-0.46-14.0%-1.56-47.9%-1.56-47.9%
Usd Book Value Change Per Share4.33133.0%0.7522.9%-0.59-18.1%0.309.2%0.309.2%
Usd Dividend Per Share0.061.8%0.031.0%0.000.1%0.020.7%0.020.7%
Usd Total Gains Per Share4.39134.8%0.7823.9%-0.59-18.0%0.329.9%0.329.9%
Usd Price Per Share0.30-0.49-2.39-2.63-2.63-
Price to Earnings Ratio-0.01--0.15--1.30--1.22--1.22-
Price-to-Total Gains Ratio0.07--0.16--4.75--5.66--5.66-
Price to Book Ratio0.06-0.32-0.76-0.63-0.63-
Price-to-Total Gains Ratio0.07--0.16--4.75--5.66--5.66-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.5230969
Number of shares283
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.030.02
Usd Book Value Change Per Share0.750.30
Usd Total Gains Per Share0.780.32
Gains per Quarter (283 shares)219.8890.99
Gains per Year (283 shares)879.54363.97
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
13684387024339354
2721687175049679718
3109253026307310181082
4145337335109813581446
51814217439012216971810
62175060527014720372174
72535903615017123762538
82906747703019627162902
93267590791022030553266
103628433879024533953630

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.017.00.00.0%0.017.00.00.0%0.017.00.00.0%
Book Value Change Per Share2.02.00.050.0%3.09.00.025.0%4.013.00.023.5%4.013.00.023.5%4.013.00.023.5%
Dividend per Share4.00.00.0100.0%12.00.00.0100.0%17.00.00.0100.0%17.00.00.0100.0%17.00.00.0100.0%
Total Gains per Share2.02.00.050.0%3.09.00.025.0%4.013.00.023.5%4.013.00.023.5%4.013.00.023.5%

Fundamentals of Cyclacel

About Cyclacel Pharmaceuticals Inc

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

Fundamental data was last updated by Penke on 2024-03-18 03:19:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Cyclacel Pharmaceuticals Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Cyclacel earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Cyclacel to the Biotechnology industry mean.
  • A Net Profit Margin of -37,700.0% means that €-377.00 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Cyclacel Pharmaceuticals Inc:

  • The MRQ is -37,700.0%. The company is making a huge loss. -2
  • The TTM is -9,790.1%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-37,700.0%TTM-9,790.1%-27,909.9%
TTM-9,790.1%YOY--9,790.1%
TTM-9,790.1%5Y-2,303.6%-7,486.6%
5Y-2,303.6%10Y-2,303.6%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-37,700.0%-159.2%-37,540.8%
TTM-9,790.1%-202.3%-9,587.8%
YOY--263.0%+263.0%
5Y-2,303.6%-452.4%-1,851.2%
10Y-2,303.6%-589.0%-1,714.6%
1.1.2. Return on Assets

Shows how efficient Cyclacel is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Cyclacel to the Biotechnology industry mean.
  • -48.3% Return on Assets means that Cyclacel generated €-0.48 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Cyclacel Pharmaceuticals Inc:

  • The MRQ is -48.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -33.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-48.3%TTM-33.7%-14.6%
TTM-33.7%YOY-13.0%-20.6%
TTM-33.7%5Y-16.2%-17.5%
5Y-16.2%10Y-16.2%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-48.3%-12.5%-35.8%
TTM-33.7%-12.2%-21.5%
YOY-13.0%-11.2%-1.8%
5Y-16.2%-13.3%-2.9%
10Y-16.2%-14.6%-1.6%
1.1.3. Return on Equity

Shows how efficient Cyclacel is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Cyclacel to the Biotechnology industry mean.
  • -140.4% Return on Equity means Cyclacel generated €-1.40 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Cyclacel Pharmaceuticals Inc:

  • The MRQ is -140.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -71.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-140.4%TTM-71.1%-69.3%
TTM-71.1%YOY-15.2%-55.9%
TTM-71.1%5Y-26.3%-44.8%
5Y-26.3%10Y-26.3%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-140.4%-16.0%-124.4%
TTM-71.1%-15.8%-55.3%
YOY-15.2%-13.9%-1.3%
5Y-26.3%-18.2%-8.1%
10Y-26.3%-19.1%-7.2%

1.2. Operating Efficiency of Cyclacel Pharmaceuticals Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Cyclacel is operating .

  • Measures how much profit Cyclacel makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Cyclacel to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated €0.00  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Cyclacel Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-397.4%+397.4%
TTM-397.4%YOY--397.4%
TTM-397.4%5Y-93.5%-303.9%
5Y-93.5%10Y-93.5%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--299.5%+299.5%
TTM-397.4%-208.5%-188.9%
YOY--280.2%+280.2%
5Y-93.5%-459.9%+366.4%
10Y-93.5%-596.9%+503.4%
1.2.2. Operating Ratio

Measures how efficient Cyclacel is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 428.81 means that the operating costs are €428.81 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Cyclacel Pharmaceuticals Inc:

  • The MRQ is 428.813. The company is inefficient in keeping operating costs low. -1
  • The TTM is 111.427. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ428.813TTM111.427+317.386
TTM111.427YOY-+111.427
TTM111.4275Y26.218+85.209
5Y26.21810Y26.2180.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ428.8132.817+425.996
TTM111.4273.181+108.246
YOY-3.609-3.609
5Y26.2185.554+20.664
10Y26.2187.396+18.822

1.3. Liquidity of Cyclacel Pharmaceuticals Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Cyclacel is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.36 means the company has €1.36 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Cyclacel Pharmaceuticals Inc:

  • The MRQ is 1.364. The company is just able to pay all its short-term debts.
  • The TTM is 2.380. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.364TTM2.380-1.016
TTM2.380YOY6.606-4.226
TTM2.3805Y8.831-6.451
5Y8.83110Y8.8310.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3643.987-2.623
TTM2.3804.440-2.060
YOY6.6065.569+1.037
5Y8.8316.158+2.673
10Y8.8316.492+2.339
1.3.2. Quick Ratio

Measures if Cyclacel is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Cyclacel to the Biotechnology industry mean.
  • A Quick Ratio of 0.00 means the company can pay off €0.00 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Cyclacel Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM0.230-0.230
TTM0.230YOY0.626-0.396
TTM0.2305Y0.637-0.407
5Y0.63710Y0.6370.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.653-3.653
TTM0.2304.158-3.928
YOY0.6265.515-4.889
5Y0.6376.012-5.375
10Y0.6376.206-5.569

1.4. Solvency of Cyclacel Pharmaceuticals Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Cyclacel assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Cyclacel to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.66 means that Cyclacel assets are financed with 65.6% credit (debt) and the remaining percentage (100% - 65.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Cyclacel Pharmaceuticals Inc:

  • The MRQ is 0.656. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.461. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.656TTM0.461+0.195
TTM0.461YOY0.143+0.318
TTM0.4615Y0.209+0.252
5Y0.20910Y0.2090.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6560.336+0.320
TTM0.4610.330+0.131
YOY0.1430.267-0.124
5Y0.2090.367-0.158
10Y0.2090.378-0.169
1.4.2. Debt to Equity Ratio

Measures if Cyclacel is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Cyclacel to the Biotechnology industry mean.
  • A Debt to Equity ratio of 190.8% means that company has €1.91 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Cyclacel Pharmaceuticals Inc:

  • The MRQ is 1.908. The company is just able to pay all its debts with equity.
  • The TTM is 0.974. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ1.908TTM0.974+0.934
TTM0.974YOY0.167+0.807
TTM0.9745Y0.348+0.626
5Y0.34810Y0.3480.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.9080.376+1.532
TTM0.9740.398+0.576
YOY0.1670.334-0.167
5Y0.3480.431-0.083
10Y0.3480.476-0.128

2. Market Valuation of Cyclacel Pharmaceuticals Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Cyclacel generates.

  • Above 15 is considered overpriced but always compare Cyclacel to the Biotechnology industry mean.
  • A PE ratio of -0.01 means the investor is paying €-0.01 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Cyclacel Pharmaceuticals Inc:

  • The EOD is -0.123. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.010. Based on the earnings, the company is expensive. -2
  • The TTM is -0.148. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.123MRQ-0.010-0.113
MRQ-0.010TTM-0.148+0.138
TTM-0.148YOY-1.295+1.147
TTM-0.1485Y-1.217+1.069
5Y-1.21710Y-1.2170.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.123-2.697+2.574
MRQ-0.010-2.422+2.412
TTM-0.148-2.709+2.561
YOY-1.295-4.116+2.821
5Y-1.217-6.257+5.040
10Y-1.217-6.478+5.261
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Cyclacel Pharmaceuticals Inc:

  • The EOD is -0.184. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.016. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.418. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.184MRQ-0.016-0.168
MRQ-0.016TTM-0.418+0.403
TTM-0.418YOY-1.411+0.993
TTM-0.4185Y-1.786+1.368
5Y-1.78610Y-1.7860.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.184-3.344+3.160
MRQ-0.016-2.939+2.923
TTM-0.418-3.486+3.068
YOY-1.411-5.592+4.181
5Y-1.786-8.464+6.678
10Y-1.786-8.872+7.086
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Cyclacel is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.06 means the investor is paying €0.06 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Cyclacel Pharmaceuticals Inc:

  • The EOD is 0.691. Based on the equity, the company is cheap. +2
  • The MRQ is 0.059. Based on the equity, the company is cheap. +2
  • The TTM is 0.320. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.691MRQ0.059+0.632
MRQ0.059TTM0.320-0.261
TTM0.320YOY0.760-0.440
TTM0.3205Y0.633-0.313
5Y0.63310Y0.6330.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.6912.198-1.507
MRQ0.0592.042-1.983
TTM0.3202.121-1.801
YOY0.7602.907-2.147
5Y0.6333.682-3.049
10Y0.6334.114-3.481
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Cyclacel Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--4.0030.689+481%-0.546+114%0.277+1344%0.277+1344%
Book Value Per Share--4.7135.657-17%2.824+67%5.927-20%5.927-20%
Current Ratio--1.3642.380-43%6.606-79%8.831-85%8.831-85%
Debt To Asset Ratio--0.6560.461+42%0.143+360%0.209+215%0.209+215%
Debt To Equity Ratio--1.9080.974+96%0.167+1044%0.348+449%0.348+449%
Dividend Per Share--0.0550.030+86%0.004+1142%0.020+174%0.020+174%
Eps---6.616-3.401-49%-0.422-94%-1.444-78%-1.444-78%
Free Cash Flow Per Share---4.427-3.109-30%-0.435-90%-1.303-71%-1.303-71%
Free Cash Flow To Equity Per Share---4.482-3.137-30%-0.353-92%-0.810-82%-0.810-82%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---270.479--------
Intrinsic Value_10Y_min---226.396--------
Intrinsic Value_1Y_max---8.427--------
Intrinsic Value_1Y_min---8.266--------
Intrinsic Value_3Y_max---39.554--------
Intrinsic Value_3Y_min---37.474--------
Intrinsic Value_5Y_max---87.841--------
Intrinsic Value_5Y_min---80.307--------
Market Cap2745175.478+92%233049.1313504957.973-93%22894685.710-99%19230035.418-99%19230035.418-99%
Net Profit Margin---377.000-97.901-74%--100%-23.036-94%-23.036-94%
Operating Margin----3.9740%-0%-0.9350%-0.9350%
Operating Ratio--428.813111.427+285%-+100%26.218+1536%26.218+1536%
Pb Ratio0.691+92%0.0590.320-82%0.760-92%0.633-91%0.633-91%
Pe Ratio-0.123-1078%-0.010-0.148+1321%-1.295+12299%-1.217+11550%-1.217+11550%
Price Per Share3.257+92%0.2770.455-39%2.208-87%2.427-89%2.427-89%
Price To Free Cash Flow Ratio-0.184-1078%-0.016-0.418+2578%-1.411+8938%-1.786+11341%-1.786+11341%
Price To Total Gains Ratio0.803+92%0.068-0.163+339%-4.748+7068%-5.664+8412%-5.664+8412%
Quick Ratio---0.230-100%0.626-100%0.637-100%0.637-100%
Return On Assets---0.483-0.337-30%-0.130-73%-0.162-67%-0.162-67%
Return On Equity---1.404-0.711-49%-0.152-89%-0.263-81%-0.263-81%
Total Gains Per Share--4.0580.718+465%-0.541+113%0.297+1265%0.297+1265%
Usd Book Value--4297136.00011019848.767-61%31861258.377-87%24963319.476-83%24963319.476-83%
Usd Book Value Change Per Share--4.3300.745+481%-0.590+114%0.300+1344%0.300+1344%
Usd Book Value Per Share--5.0986.119-17%3.055+67%6.411-20%6.411-20%
Usd Dividend Per Share--0.0590.032+86%0.005+1142%0.022+174%0.022+174%
Usd Eps---7.157-3.679-49%-0.456-94%-1.562-78%-1.562-78%
Usd Free Cash Flow---4036127.739-4344387.496+8%-5054159.959+25%-3508287.504-13%-3508287.504-13%
Usd Free Cash Flow Per Share---4.789-3.363-30%-0.471-90%-1.409-71%-1.409-71%
Usd Free Cash Flow To Equity Per Share---4.848-3.393-30%-0.382-92%-0.876-82%-0.876-82%
Usd Market Cap2969456.315+92%252089.2453791313.040-93%24765181.533-99%20801129.312-99%20801129.312-99%
Usd Price Per Share3.523+92%0.2990.492-39%2.388-87%2.625-89%2.625-89%
Usd Profit---6032190.913-6175945.462+2%-4768400.915-21%-4118953.890-32%-4118953.890-32%
Usd Revenue--16000.50697253.078-84%-+100%22883.077-30%22883.077-30%
Usd Total Gains Per Share--4.3900.777+465%-0.586+113%0.322+1265%0.322+1265%
 EOD+6 -2MRQTTM+11 -23YOY+13 -215Y+9 -2510Y+9 -25

3.2. Fundamental Score

Let's check the fundamental score of Cyclacel Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.123
Price to Book Ratio (EOD)Between0-10.691
Net Profit Margin (MRQ)Greater than0-377.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.000
Current Ratio (MRQ)Greater than11.364
Debt to Asset Ratio (MRQ)Less than10.656
Debt to Equity Ratio (MRQ)Less than11.908
Return on Equity (MRQ)Greater than0.15-1.404
Return on Assets (MRQ)Greater than0.05-0.483
Total3/10 (30.0%)

3.3. Technical Score

Let's check the technical score of Cyclacel Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5044.711
Ma 20Greater thanMa 503.257
Ma 50Greater thanMa 1003.191
Ma 100Greater thanMa 2004.398
OpenGreater thanClose3.257
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets12,497
Total Liabilities8,200
Total Stockholder Equity4,297
 As reported
Total Liabilities 8,200
Total Stockholder Equity+ 4,297
Total Assets = 12,497

Assets

Total Assets12,497
Total Current Assets11,113
Long-term Assets1,384
Total Current Assets
Cash And Cash Equivalents 5,944
Other Current Assets 1,950
Total Current Assets  (as reported)11,113
Total Current Assets  (calculated)7,894
+/- 3,219
Long-term Assets
Property Plant Equipment 125
Long-term Assets  (as reported)1,384
Long-term Assets  (calculated)125
+/- 1,259

Liabilities & Shareholders' Equity

Total Current Liabilities8,148
Long-term Liabilities52
Total Stockholder Equity4,297
Total Current Liabilities
Accounts payable 1,571
Other Current Liabilities 356
Total Current Liabilities  (as reported)8,148
Total Current Liabilities  (calculated)1,927
+/- 6,221
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt52
Long-term Liabilities  (as reported)52
Long-term Liabilities  (calculated)52
+/-0
Total Stockholder Equity
Total Stockholder Equity (as reported)4,297
Total Stockholder Equity (calculated)0
+/- 4,297
Other
Capital Stock12
Common Stock Shares Outstanding 843
Net Invested Capital 4,297
Net Working Capital 2,965
Property Plant and Equipment Gross 125



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-30
> Total Assets 
17,077
15,308
12,987
29,171
27,213
36,802
51,817
46,334
44,999
42,587
39,629
35,346
31,021
27,501
22,060
16,442
12,497
12,49716,44222,06027,50131,02135,34639,62942,58744,99946,33451,81736,80227,21329,17112,98715,30817,077
   > Total Current Assets 
15,836
14,017
11,811
27,933
25,934
35,469
50,463
46,203
43,375
40,942
36,577
32,077
27,915
24,411
18,974
15,294
11,113
11,11315,29418,97424,41127,91532,07736,57740,94243,37546,20350,46335,46925,93427,93311,81114,01715,836
       Cash And Cash Equivalents 
12,967
11,885
8,923
25,342
23,130
33,406
47,777
43,639
40,219
36,559
29,639
29,077
23,706
18,345
11,435
10,164
5,944
5,94410,16411,43518,34523,70629,07729,63936,55940,21943,63947,77733,40623,13025,3428,92311,88512,967
       Net Receivables 
1,929
1,326
1,525
1,805
2,166
1,313
2,010
1,586
2,514
3,727
4,732
2,000
2,791
4,664
0
1,953
0
01,95304,6642,7912,0004,7323,7272,5141,5862,0101,3132,1661,8051,5251,3261,929
       Other Current Assets 
119
103
1,070
104
140
66
228
142
112
79
1,539
79
170
426
595
2,186
1,950
1,9502,186595426170791,53979112142228661401041,070103119
   > Long-term Assets 
1,241
1,291
1,176
1,238
1,279
1,333
1,354
131
1,624
1,645
3,052
3,269
3,106
3,090
3,086
1,148
1,384
1,3841,1483,0863,0903,1063,2693,0521,6451,6241311,3541,3331,2791,2381,1761,2911,241
       Property Plant Equipment 
1,241
1,291
1,176
1,238
1,279
1,333
1,354
131
115
94
72
209
190
174
170
148
125
12514817017419020972941151311,3541,3331,2791,2381,1761,2911,241
       Other Assets 
0
0
0
0
0
0
0
0
1,509
1,551
2,980
3,060
2,916
2,916
0
1,000
0
01,00002,9162,9163,0602,9801,5511,50900000000
> Total Liabilities 
3,225
3,611
2,596
2,593
2,775
3,543
3,768
3,118
3,635
5,324
6,219
5,139
4,460
11,992
7,418
6,812
8,200
8,2006,8127,41811,9924,4605,1396,2195,3243,6353,1183,7683,5432,7752,5932,5963,6113,225
   > Total Current Liabilities 
2,071
2,420
1,523
1,512
1,712
2,486
2,772
3,118
3,591
5,294
6,204
5,026
4,353
7,392
7,338
6,746
8,148
8,1486,7467,3387,3924,3535,0266,2045,2943,5913,1182,7722,4861,7121,5121,5232,4202,071
       Accounts payable 
887
890
250
342
455
514
871
1,197
1,515
2,117
2,850
2,205
983
2,561
2,509
2,169
1,571
1,5712,1692,5092,5619832,2052,8502,1171,5151,197871514455342250890887
       Other Current Liabilities 
198
678
215
408
475
866
398
264
125
634
118
558
172
887
223
234
356
356234223887172558118634125264398866475408215678198
   > Long-term Liabilities 
1,154
1,191
1,073
1,081
1,063
1,057
996
0
44
30
15
113
107
4,600
80
66
52
5266804,60010711315304409961,0571,0631,0811,0731,1911,154
       Capital Lease Obligations Min Short Term Debt
1,154
1,191
1,073
1,081
1,063
1,057
996
0
44
30
15
113
107
106
80
66
52
52668010610711315304409961,0571,0631,0811,0731,1911,154
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
4,494
4,494
0
4,494
0
04,49404,4944,494000000000000
> Total Stockholder Equity
13,852
11,697
10,391
26,578
24,438
33,259
48,049
43,216
41,364
37,263
33,410
30,207
26,561
15,509
14,642
9,630
4,297
4,2979,63014,64215,50926,56130,20733,41037,26341,36443,21648,04933,25924,43826,57810,39111,69713,852
   Common Stock
17
17
1
5
5
6
9
9
10
10
10
11
9
9
0
9
0
09099111010109965511717
   Retained Earnings Total Equity00000000000000000
   Accumulated Other Comprehensive Income 00000000000000000
   Capital Surplus 00000000000000000
   Treasury Stock00000000000000000
   Other Stockholders Equity 0-1,0970-1,316-1,746-1,276-823-748-753-658-730-746-881-934-946-819-913



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue389
Cost of Revenue--
Gross Profit-389
 
Operating Income (+$)
Gross Profit-
Operating Expense-29,327
Operating Income-28,938-29,327
 
Operating Expense (+$)
Research Development22,339
Selling General Administrative6,988
Selling And Marketing Expenses-
Operating Expense29,32729,327
 
Net Interest Income (+$)
Interest Income365
Interest Expense--
Other Finance Cost-0
Net Interest Income365
 
Pretax Income (+$)
Operating Income-28,938
Net Interest Income365
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-28,858-28,653
EBIT - interestExpense = 0
-24,703
-24,703
Interest Expense-
Earnings Before Interest and Taxes (EBIT)--28,858
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-28,858
Tax Provision--4,155
Net Income From Continuing Ops-24,703-24,703
Net Income-24,703
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-285-365
 

Technical Analysis of Cyclacel
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Cyclacel. The general trend of Cyclacel is BEARISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Cyclacel's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-71.4%) Bearish trend (71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Cyclacel Pharmaceuticals Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 3.257 < 3.257 < 3.257.

The bearish price targets are: 3.257 > 3.257 > 3.257.

Tweet this
Cyclacel Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Cyclacel Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 2/14.
The longshort score for the Moving Averages is -10/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Cyclacel Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Cyclacel Pharmaceuticals Inc. The current macd is -0.01897303.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Cyclacel price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Cyclacel. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Cyclacel price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Cyclacel Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartCyclacel Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Cyclacel Pharmaceuticals Inc. The current adx is 39.74.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Cyclacel shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
Cyclacel Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Cyclacel Pharmaceuticals Inc. The current sar is 2.890716.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Cyclacel Pharmaceuticals Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Cyclacel Pharmaceuticals Inc. The current rsi is 44.71. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -3/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
Cyclacel Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartCyclacel Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Cyclacel Pharmaceuticals Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Cyclacel price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Cyclacel Pharmaceuticals Inc Daily Stochastic Oscillator ChartCyclacel Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Cyclacel Pharmaceuticals Inc. The current cci is 66.67.

Cyclacel Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartCyclacel Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Cyclacel Pharmaceuticals Inc. The current cmo is 0.20066402.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Cyclacel Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartCyclacel Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Cyclacel Pharmaceuticals Inc. The current willr is 0.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Cyclacel Pharmaceuticals Inc Daily Williams %R ChartCyclacel Pharmaceuticals Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Cyclacel Pharmaceuticals Inc.

Cyclacel Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Cyclacel Pharmaceuticals Inc. The current atr is 0.0358504.

Cyclacel Pharmaceuticals Inc Daily Average True Range (ATR) ChartCyclacel Pharmaceuticals Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Cyclacel Pharmaceuticals Inc. The current obv is 252.00.

Cyclacel Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartCyclacel Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Cyclacel Pharmaceuticals Inc. The current mfi is 0.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Cyclacel Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartCyclacel Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Cyclacel Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-09-27 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2023-09-29 00:00:00CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-10-02 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2023-10-05 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-10-09 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2023-10-10 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-10-11 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-10-12 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2023-10-13 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2023-10-16 00:00:00MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-10-17 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2023-10-18 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2023-10-19 00:00:00RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-10-27 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-10-31 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-01 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-03 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-11-06 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-07 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-11-08 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-10 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-13 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-17 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-28 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-30 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-04 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-05 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-12 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-13 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-15 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-18 00:00:00CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-20 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-03 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-05 00:00:00WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-09 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Cyclacel Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Cyclacel Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5044.711
Ma 20Greater thanMa 503.257
Ma 50Greater thanMa 1003.191
Ma 100Greater thanMa 2004.398
OpenGreater thanClose3.257
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Cyclacel with someone you think should read this too:
  • Are you bullish or bearish on Cyclacel? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Cyclacel? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Cyclacel Pharmaceuticals Inc

I send you an email if I find something interesting about Cyclacel Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Cyclacel Pharmaceuticals Inc.

Receive notifications about Cyclacel Pharmaceuticals Inc in your mailbox!